News

Tuesday, 15. December 2020 | Filed under Company News

Allero Therapeutics Expands Management Team with Two Key Hires

Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, today announced the appointment of two key members to its management team.

As of December 1, 2020, Steven Glazer has joined the Company as Chief Medical Officer and Christophe Saillez as Vice President Regulatory Affairs.

Read more…

Tuesday, 8. December 2020 | Filed under Company News

Company News: First-In-Human Heart Failure Data of Cardior Pharmaceuticals´ Novel miRNA Antisense Therapy Presented at the 17th Global Cardiovascular Clinical Trialists Forum

Excellent safety and tolerability of first-in-class compound CDR132L

— Novel mode of action confirmed by data on cardiac function and biomarkers

Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, today announced that its Chief Scientific Officer Thomas Thum, MD, PhD, has presented clinical data on the Company´s lead compound CDR131L at the 17th Global Cardiovascular Clinical Trialists Forum (CVCT) on December 7, 2020.

Read more…

Tuesday, 24. November 2020 | Filed under Company News

Company News: Allero Therapeutics and Abbreos Join Forces to Clinically Develop COVID-19 Program

Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive immune responses, today announced a clinical development agreement to treat medical conditions associated with potentially lethal amounts of pro-inflammatory cytokines and chemokines (“cytokine storm”). A first focus of the agreement is the treatment of patients likely to progress into COVID-19-associated acute respiratory distress syndrome (ARDS).

Read more…